Dr. Jianqing Zhu 朱笕青
Chief Physician
Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of gynecologic tumors, with a focus on surgery and chemotherapy for ovarian cancer.
Dr. Zhu graduated from Zhejiang Medical University in August 1987 and has worked in the gynecology department of Zhejiang Cancer Hospital since. As Director of Gynecologic Surgery, Dr. Zhu performs surgery, chemotherapy, and postoperative radiotherapy for malignant gynecologic tumors. Research focuses on basic and clinical studies of ovarian cancer. Dr. Zhu has led three research projects, published over 50 papers, and co-authored six books.
Professional roles
- Standing Committee Member, Gynecologic Oncology Committee, China Anti-Cancer Association
- Member, Gynecologic Oncology Committee, Zhejiang Anti-Cancer Association
- Council Member, Zhejiang Medical Association
- Editorial Board Member, International Journal of Gynecology and Obstetrics
Name order: in Chinese the family name comes first (Zhu Jianqing). Papers usually list the name as Jianqing Zhu or Zhu J.
Selected publications
68 papers on PubMed matched by name and affiliation; 13 as first or senior author since 2016. Most recent first- or senior-author papers:
- Am J Hematol, 2026 (senior author): SHR-2004, a Humanized Monoclonal Antibody Targeting Factor XI, for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active-Controlled Phase 2 Study. PubMed 42644221
- J Obstet Gynaecol Res, 2026 (senior author): Efficacy and Safety of Pamiparib Monotherapy in Recurrent Ovarian Cancer After Prior PARPi Exposure: A Prospective, Open-Label, Single-Arm, Phase II Study. PubMed 42051038
- EClinicalMedicine, 2025 (senior author): A phase 2 study of tislelizumab combined with bevacizumab and chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer. PubMed 40673010
- Int J Cancer, 2024 (senior author): Glycolysis regulation in tumor-associated macrophages: Its role in tumor development and cancer treatment. PubMed 37688376
- J Obstet Gynaecol Res, 2023 (senior author): Pulmonary metastasectomy for recurrent metastatic ovarian cancer. PubMed 37813122
- J Cancer Res Clin Oncol, 2023 (senior author): T cells with split CARs specific for NKG2D ligands and PD-L1 exhibit improved selectivity towards monocyte-derived cells while effective in eliminating acute myeloid leukaemia in vivo. PubMed 37270461
- J Proteomics, 2023 (senior author): Proteomic analysis reveals CAAP1 negatively correlates with platinum resistance in ovarian cancer. PubMed 36870674
- Cancer Immunol Immunother, 2023 (senior author): Dual CAR-T cells to treat cancers co-expressing NKG2D and PD1 ligands in xenograft models of peritoneal metastasis. PubMed 35809118
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion